{"id":"NCT00395018","sponsor":"Bristol-Myers Squibb","briefTitle":"Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection","officialTitle":"Study of the Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-04","primaryCompletion":"2011-03","completion":"2011-03","firstPosted":"2006-11-02","resultsPosted":"2012-05-31","lastUpdate":"2012-05-31"},"enrollment":109,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Hepatitis B, Chronic"],"interventions":[{"type":"DRUG","name":"entecavir","otherNames":["Baraclude","BMS-200475"]}],"arms":[{"label":"entecavir","type":"EXPERIMENTAL"}],"summary":"The purpose of this clinical research study is to learn if the study drug entecavir will prevent the recurrence of hepatitis B virus (HBV) in participants who receive an orthotopic liver transplant (OLT) due to HBV infection.","primaryOutcome":{"measure":"Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) => 50 IU/mL by Polymerase Chain Reaction (PCR) at Week 72","timeFrame":"At 72 weeks","effectByArm":[{"arm":"Entecavir (ETV)","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":32,"countries":["United States","Argentina","Australia","Brazil","France","Italy","South Korea","Spain","Taiwan"]},"refs":{"pmids":[],"seeAlso":["http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":36,"n":65},"commonTop":["Hypertension","Diarrhoea","Abdominal pain","Hyperglycaemia","Headache"]}}